stockrow
Saturday 7 November 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
- EPS
- +94.7%
- Free cash flow
- −879.2%
Quarter to June 2026, against a year earlier
1.91
0.21
−9.91%
Follow ARTL
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (705.71%) | (367.70%) | (1,625.11%) | (436.14%) |
+8 more TTM periods Free account |
|
| (234.30%) | (167.97%) | (343.49%) | (219.08%) | ||
ROIC |
(865.85%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(434.53%) | (293.16%) | 384.56% | 411.84% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(41.93) | (98.83) | (105.09) | (280.96) | |
Free Cash Flow |
(12.63) | (8.11) | (8.52) | (8.18) | |
| Other line items | |||||
Cash ROIC |
(137.39%) | (47.88%) | 1,267.86% | (752.16%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(33.04) | (29.21) | (40.44) | (65.77) | |
Operating CF/Net income |
1.00 | 0.60 | 0.66 | 0.65 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(41.93) | (98.83) | (105.09) | (280.96) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026